...
首页> 外文期刊>Cerebrovascular diseases >Enlargement of acute intracerebral hematomas in patients on long-term warfarin treatment.
【24h】

Enlargement of acute intracerebral hematomas in patients on long-term warfarin treatment.

机译:长期使用华法林治疗的患者急性脑血肿扩大。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: The relationship between warfarin administration and the frequent development of enlarged hematomas in patients with acute intracerebral hemorrhage (ICH) is controversial. The present study was carried out to examine this issue. METHODS: This study reviewed 41 patients with nontraumatic ICH within 24 h after stroke onset from 1999 to 2003 who received long-term warfarin treatment (29 men and 12 women, 70 +/- 12 years old) and 323 patients who had not been on warfarin (177 men and 146 women, 66 +/- 13 years old). The hematoma volume (HV) on admission, final HV, frequency of hematoma enlargement (HE) and other background characteristics were investigated. RESULTS: Both the HV on admission (p = 0.031) and final HV (p = 0.001) were larger in patients on warfarin than in those not receiving warfarin. HE occurred more frequently (p < 0.001), and mortality at 30 days or at discharge was higher (p = 0.003) in the warfarin group than in the control group. A multivariate adjusted logistic regression analysis showed that warfarin treatment (OR = 5.75, 95% CI = 2.41-13.8, p < 0.001), liver disease (OR = 2.59, 95% CI = 1.12-5.99, p = 0.026), and the National Institutes of Health Stroke Scale score (OR = 1.10, 95% CI = 1.04-1.15, p < 0.001, per 1-score increase) on admission were independently related to HE. CONCLUSIONS: Acute ICH in patients on long-term warfarin treatment appears to be associated with HE.
机译:背景:华法林给药与急性脑出血(ICH)患者频繁发生扩大的血肿之间的关系存在争议。进行本研究以研究此问题。方法:本研究回顾了1999年至2003年中风发作后24小时内接受长期华法林治疗的41例非创伤性ICH患者(29例男性和12例女性,70 +/- 12岁)和323例未接受过华法林治疗的患者。华法林(177名男性和146名女性,66 +/- 13岁)。研究了入院时的血肿量(HV),最终HV,血肿扩大的频率(HE)和其他背景特征。结果:华法林组患者入院时的HV(p = 0.031)和最终HV(p = 0.001)均大于未接受华法林的患者。华法林组HE的发生频率更高(p <0.001),在30天或出院时的死亡率高于对照组(p = 0.003)。多元校正logistic回归分析显示,华法林治疗(OR = 5.75,95%CI = 2.41-13.8,p <0.001),肝病(OR = 2.59,95%CI = 1.12-5.99,p = 0.026),且美国国立卫生研究院卒中量表评分(OR = 1.10,95%CI = 1.04-1.15,p <0.001,每增加1分)独立于HE。结论:长期接受华法林治疗的患者的急性ICH似乎与HE有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号